Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.
Bain
C
C
Department of Tumor Biology, Centre Léon Bérard, Lyon, France.
Merrouche
Y
Y
Puisieux
I
I
Blay
J Y
JY
Negrier
S
S
Bonadona
V
V
Lasset
C
C
Lanier
F
F
Duc
A
A
Gebuhrer
L
L
Philip
T
T
Favrot
M C
MC
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005787:Gene Frequency; D006680:HLA Antigens / Q000032:analysis* / Q000235:genetics; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis
D006680:HLA Antigens; D007376:Interleukin-2